Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713574 | 0.72 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL576624 | 0.70 | ELANE (0.39) | MMP2MMP9MMP8MMP13LMNA | |
| SCHEMBL10073523 | 0.70 | CYP1A2 (0.39) | MEN1KMT2AHTT | |
| SCHEMBL713890 | 0.70 | CYP1A2 (0.39) | MEN1KMT2AHTT | |
| SCHEMBL549395 | 0.69 | MMP2 (0.42) | MMP2MMP9MMP8MMP13MEN1 | |
| SCHEMBL712684 | 0.67 | POLB (0.41) | — | |
| SCHEMBL13282109 | 0.65 | FASN (0.43) | PLA2G6PLA2G4AMEN1KMT2AALDH1A1 | |
| SCHEMBL13282110 | 0.65 | MEN1 (0.38) | GRM2MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL6864572 | 0.65 | CYP1A2 (0.43) | ALDH1A1 | |
| SCHEMBL713575 | 0.64 | MMP2 (0.46) | MMP2MMP9MMP8MMP13MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124794-B2 | Method for the asymmetric synthesis of beta-lactone compounds | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | claimed |
| US-20100173982-A1 | NOVEL METHOD FOR THE ASYMMETRIC SYNTHESIS OF BETA-LACTONE COMPOUNDS | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-07-08 | — | — | US | claimed |
| US-8124794-B2 | Method for the asymmetric synthesis of beta-lactone compounds | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100173982-A1 | NOVEL METHOD FOR THE ASYMMETRIC SYNTHESIS OF BETA-LACTONE COMPOUNDS | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-07-08 | — | — | US | disclosed |
| US-7728153-B2 | Method for the asymmetric synthesis of beta-lactone compounds | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-06-01 | — | — | US | disclosed |
| US-20060258620-A1 | Novel method for the asymmetric synthesis of beta-lactone compounds | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173982-A1 | NOVEL METHOD FOR THE ASYMMETRIC SYNTHESIS OF BETA-LACTONE COMPOUNDS | FASN, COASY, FADS1 | MMP2 1131/4885MMP9 1562/4885MMP8 2002/4885 |
| US-20060258620-A1 | Novel method for the asymmetric synthesis of beta-lactone compounds | FASN, COASY, FADS1 | MMP2 1131/4885MMP9 1562/4885MMP8 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.